Your browser doesn't support javascript.
loading
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar, Rachel L; Liu, Suyu; Tai, Mei Chee; Rajapakshe, Kimal; Huang, Ying; Longton, Gary; DeCapite, Christine; Hurd, Mark W; Paris, Pamela L; Kirkwood, Kimberly S; Coarfa, Cristian; Maitra, Anirban; Brand, Randall E; Killary, Ann M; Sen, Subrata.
Afiliación
  • Dittmar RL; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu S; University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.
  • Tai MC; University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, Texas.
  • Rajapakshe K; Department of Biostatistics, Division of Science, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang Y; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Longton G; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
  • DeCapite C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Hurd MW; Department of Biostatistics University of Washington, Seattle, Washington.
  • Paris PL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Kirkwood KS; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Coarfa C; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maitra A; Department of Urology and Division of Hematology Oncology, UCSF Helen Diller Cancer Research Center, San Francisco, California.
  • Brand RE; Department of Surgery, Division of General Surgery, UCSF Helen Diller Cancer Research Center, San Francisco, California.
  • Killary AM; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
  • Sen S; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Cancer Prev Res (Phila) ; 14(7): 729-740, 2021 07.
Article en En | MEDLINE | ID: mdl-33893071
Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 µL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66-0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63-0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58-0.81) were identified as significantly differentially abundant in plasma from stage II PDAC versus controls. Although none of the miRNAs individually outperformed the currently used serologic biomarker for PDAC, carbohydrate antigen 19-9 (CA19-9), combining the miRNAs with CA 19-9 improved AUCs from 0.89 (95% CI, 0.81-0.95) for CA 19-9 alone to 0.92 (95% CI, 0.86-0.97), 0.94 (95% CI, 0.89-0.98), and 0.92 (95% CI, 0.87-0.97), respectively. Gene set enrichment analyses of transcripts correlated with high and low expression of the three miRNAs in The Cancer Genome Atlas PDAC sample set. These miRNA biomarkers, assayed in limited volume plasma together with CA19-9, discriminate stage II PDAC from controls with good sensitivity and specificity. Unbiased profiling of larger cohorts should help develop an informative early detection biomarker assay for diagnostic settings. PREVENTION RELEVANCE: Development of minimally invasive biomarker assays for detection of premalignant disease and early-stage pancreatic cancer is key to improving patient survival. This study describes a limited volume plasma miRNA biomarker assay that can detect early-stage resectable pancreatic cancer in clinical samples necessary for effective prevention and clinical intervention.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Antígeno CA-19-9 / Carcinoma Ductal Pancreático / MicroARNs / Detección Precoz del Cáncer Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Screening_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Prev Res (Phila) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Antígeno CA-19-9 / Carcinoma Ductal Pancreático / MicroARNs / Detección Precoz del Cáncer Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Screening_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Prev Res (Phila) Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
...